https://scholars.lib.ntu.edu.tw/handle/123456789/641591
標題: | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | 作者: | Sangro, B Chan, S L Kelley, R K Lau, G Kudo, M Sukeepaisarnjaroen, W Yarchoan, M De Toni, E N Furuse, J Kang, Y K Galle, P R Rimassa, L Heurgué, A Tam, V C Van Dao, T Thungappa, S C Breder, V Ostapenko, Y Reig, M Makowsky, M Paskow, M J Gupta, C Kurland, J F Negro, A Abou-Alfa, G K ANN-LII CHENG |
關鍵字: | durvalumab; immune checkpoint inhibitor; overall survival; tremelimumab; unresectable hepatocellular carcinoma | 公開日期: | 19-二月-2024 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641591 | ISSN: | 09237534 | DOI: | 10.1016/j.annonc.2024.02.005 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。